{"title":"单用索拉非尼治疗晚期肝细胞癌患者的暂时缓解- 1例报告和文献复习","authors":"S. Elder, Yixing Jiang","doi":"10.15761/crr.1000180","DOIUrl":null,"url":null,"abstract":"Hepatocellular carcinoma (HCC) is a primary liver tumor which has been increasing in incidence over the past several years [1], and is the second leading cause of cancer death in the world [2]. Advanced HCC usually carries a poor prognosis. Over the past decade, systemic therapy for HCC has been evolving rapidly offering more therapeutic options and longer survival for those with incurable HCC. Here, we report a case of advanced HCC treated with single agent sorafenib and achieved complete radiographic response. In this article, we also provide a summary of current status of systemic therapy for HCC. *Correspondence to: Yixing Jiang, Marlene and Stewart Greenebaum Cancer Center, University of Maryland Medical Center, Baltimore, USA, E-mail: yjiang@umm.edu","PeriodicalId":91850,"journal":{"name":"Cancer reports and reviews","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Temporary remission of advanced hepatocellular carcinoma in a patient treated with sorafenib therapy alone - A case report and literature review\",\"authors\":\"S. Elder, Yixing Jiang\",\"doi\":\"10.15761/crr.1000180\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Hepatocellular carcinoma (HCC) is a primary liver tumor which has been increasing in incidence over the past several years [1], and is the second leading cause of cancer death in the world [2]. Advanced HCC usually carries a poor prognosis. Over the past decade, systemic therapy for HCC has been evolving rapidly offering more therapeutic options and longer survival for those with incurable HCC. Here, we report a case of advanced HCC treated with single agent sorafenib and achieved complete radiographic response. In this article, we also provide a summary of current status of systemic therapy for HCC. *Correspondence to: Yixing Jiang, Marlene and Stewart Greenebaum Cancer Center, University of Maryland Medical Center, Baltimore, USA, E-mail: yjiang@umm.edu\",\"PeriodicalId\":91850,\"journal\":{\"name\":\"Cancer reports and reviews\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer reports and reviews\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15761/crr.1000180\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer reports and reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15761/crr.1000180","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
肝细胞癌(HCC)是一种原发性肝脏肿瘤,其发病率在过去几年中呈上升趋势,是全球癌症死亡的第二大原因。晚期HCC通常预后较差。在过去的十年中,HCC的全身治疗发展迅速,为无法治愈的HCC患者提供了更多的治疗选择和更长的生存期。在这里,我们报告了一例晚期HCC单药索拉非尼治疗并获得完全放射学反应。在本文中,我们也对肝细胞癌的全身治疗现状进行了总结。*通讯:美国巴尔的摩马里兰大学医学中心蒋宜兴,Marlene and Stewart Greenebaum癌症中心,E-mail: yjiang@umm.edu
Temporary remission of advanced hepatocellular carcinoma in a patient treated with sorafenib therapy alone - A case report and literature review
Hepatocellular carcinoma (HCC) is a primary liver tumor which has been increasing in incidence over the past several years [1], and is the second leading cause of cancer death in the world [2]. Advanced HCC usually carries a poor prognosis. Over the past decade, systemic therapy for HCC has been evolving rapidly offering more therapeutic options and longer survival for those with incurable HCC. Here, we report a case of advanced HCC treated with single agent sorafenib and achieved complete radiographic response. In this article, we also provide a summary of current status of systemic therapy for HCC. *Correspondence to: Yixing Jiang, Marlene and Stewart Greenebaum Cancer Center, University of Maryland Medical Center, Baltimore, USA, E-mail: yjiang@umm.edu